Bespak, at Holmes Chapel, specialises in inhaled and nasal drugs for conditions such as asthma. “This propellant has a near-zero global warming potential compared to the propellants that are currently used, which are classed as greenhouse gases. “The new facility will enable Bespak to service the increasing demand from global pharmaceutical companies developing more sustainable inhalers. “Overall, the proposed scheme will significantly enhance the site’s capabilities for the advanced manufacturing, packaging, and distribution of respiratory medical devices, specifically inhalers.”The company says the expansion will create about 150 new jobs at the Holmes Chapel site. It will also generate construction jobs during development and associated economic investment from build costs.